Smith+Nephew has announced that David King will join the board as an independent non-executive director with effect from 1 July 2025. He will serve as a member of the compliance & culture and the remuneration committees.
King is currently CEO, executive director and chair of Fortis Life Sciences. He also serves, or has recently served, as a chair or non-executive director on the boards of several US healthcare companies, including ZimVie (2022-2025), VaxCare (2021-2025), Privia Health, Health Channels, LGC and AmSurg Corporation.
King served as executive chair and CEO for Laboratory Corporation of America (LabCorp) from 2007 to 2020 and prior to that was a partner at Hogan & Hartson LLP (now Hogan Lovells).
Rupert Soames, chair of Smith+Nephew, commented: “We are delighted to welcome David to our board. He has extensive experience in the healthcare and life sciences sectors helping to transform and grow businesses in the US and globally.”
Related Posts
-
June 13, 2024
The former TSB chief operating officer will become a non-executive director of the global travel and high street retailer from next month.
-
January 14, 2025
She will join the global medical technology company’s board as an independent NED, with effect from next month.
-
February 7, 2024
Situl Jobanputra will join the board of the global travel and high street retail chain from 1 March this year.
-
March 25, 2025
Weir Group’s digital chief has become a non-executive director of the company—a supplier to the construction industry—with immediate effect.
